Back to top
more

Organogenesis (ORGO)

(Delayed Data from NSDQ)

$2.35 USD

2.35
903,642

+0.07 (2.84%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $2.35 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ORGO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Organogenesis falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 104 103 115 85 60
Receivables 82 89 82 57 39
Notes Receivable 0 0 0 0 0
Inventories 28 25 25 28 23
Other Current Assets 10 5 5 5 3
Total Current Assets 225 223 227 174 126
Net Property & Equipment 116 102 79 60 47
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 28 30 32 0 0
Intangibles 45 50 54 59 46
Deposits & Other Assets 6 2 2 1 1
Total Assets 460 449 443 294 221
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 3 17 0
Accounts Payable 31 32 29 23 28
Current Portion Long-Term Debt 5 5 0 0 0
Current Portion Capital Leases 1 0 0 4 3
Accrued Expenses 30 26 37 24 23
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 1 1 5
Total Current Liabilities 81 75 82 68 60
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 2 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 61 66 71 53 83
Non-Current Capital Leases 2 0 0 11 14
Other Non-Current Liabilities 1 1 2 13 7
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 181 184 201 148 165
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 320 311 302 299 227
Retained Earnings -41 -45 -60 -153 -171
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 279 266 242 146 56
Total Liabilities & Shareholder's Equity 460 449 443 294 221
Total Common Equity 279 266 242 146 56
Shares Outstanding 132.00 130.90 128.60 107.70 94.70
Book Value Per Share 2.11 2.03 1.88 1.36 0.59

Fiscal Year End for Organogenesis falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 104 99 90 89
Receivables NA 82 89 94 92
Notes Receivable NA 0 0 0 0
Inventories NA 28 28 25 26
Other Current Assets NA 10 10 8 10
Total Current Assets NA 225 226 216 217
Net Property & Equipment NA 116 118 112 107
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 28 30 30 30
Intangibles NA 45 46 47 48
Deposits & Other Assets NA 6 1 1 1
Total Assets NA 460 463 450 446
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 5 0
Accounts Payable NA 31 27 27 30
Current Portion Long-Term Debt NA 5 5 0 5
Current Portion Capital Leases NA 1 1 0 0
Accrued Expenses NA 30 35 28 29
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 81 81 73 76
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 61 62 63 65
Non-Current Capital Leases NA 2 2 0 0
Other Non-Current Liabilities NA 1 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 181 186 179 182
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 320 317 315 313
Retained Earnings NA -41 -40 -44 -49
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 279 277 271 264
Total Liabilities & Shareholder's Equity NA 460 463 450 446
Total Common Equity 0 279 277 271 264
Shares Outstanding 131.90 132.00 131.30 131.20 131.20
Book Value Per Share 0.00 2.11 2.11 2.07 2.01